GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn ...

GSK GSK-0.10%decrease; red down pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

Oct 8 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients ...

FDA accepted GSK's gepotidacin application for uUTI treatment with a PDUFA date set for March 26, 2025. Gepotidacin showed superior efficacy over nitrofurantoin in EAGLE-3 trial with a 58.5% ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline. Depemokimab helped ...

We recently made a list of the 10 Best Global Stocks To Buy Now. In this piece, we will look at where GSK plc (NYSE:GSK) ranks among the top ten global stocks to buy. With the third quarter of ...

The GSK share price has had a rotten few years and now it’s heading south yet again. Investor Harvey Jones continues to hang on in the hope that it will recover. When investing, your capital is ...

GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before litigation started in summer 2022. The drugs group rose 5% or 77.5p to 1535 ...

GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to meet its primary ...